AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02569346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq crushed + drip feed
Description: Drip feed followed by single-dose crushed and suspended tablet of Triumeq
Study NCT02569346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triumeq crushed + drip feed
Description: Drip feed followed by single-dose crushed and suspended tablet of Triumeq
Study NCT00541268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
Study NCT02599480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron
Description: 50 mg daily during 12 months
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: Echocardiography
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Echocardiography
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac MRI
Description: Cardiac MRI
Study NCT02103036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises (CSE)
Description: The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
Study NCT02103036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Back School
Description: The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
Study NCT02103036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes.
Study NCT02103036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infra-red
Description: Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: Cardiac MRI
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maximal exercise capacity
Description: Maximal exercise capacity
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximal exercise capacity
Description: Maximal exercise capacity
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling for study assessments and future exploratory studies.
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling for study assessments and future exploratory studies.
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endothelial function measurement
Description: EndoPAT assessment
Study NCT02599480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial function measurement
Description: EndoPAT assessment
Study NCT02599480 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 18FDG-PET
Description: PET scanning for beige/brown fat activation
Study NCT02599480 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18FDG-PET
Description: PET scanning for beige/brown fat activation
Study NCT00769236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and biopsy
Description: Biopsy and blood : Research for various antibodies
Study NCT00769236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and blood sampling
Description: Biopsy and blood : research for various antibodies
Study NCT00769236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and blood sampling
Description: Blood and biopsy : research for various antibodies
Study NCT02941289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual search performance of everyday objects in realistic scenes
Study NCT02941289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visual search performance of everyday objects in realistic scenes
Study NCT03084289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63-METRAP
Description: The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
Study NCT03731403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI varnish
Description: CPP- ACP with 5 % sodium fluoride GC
Study NCT04190316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU
Description: ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
Study NCT03731403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI varnish
Description: CPP- ACP with 5 % sodium fluoride GC
Study NCT02574728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
Study NCT02574728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
Study NCT02574728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
Study NCT02574728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
Study NCT04073199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long Lever Group
Description: the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate).
Study NCT04073199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Lever Group
Description: It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)
Study NCT03084289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA ME-TRAP
Description: The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
Study NCT02308319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 300mg q.d. per oral
Study NCT02308319 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir disoproxil fumarate
Description: 300mg q.d. per oral
Study NCT02660970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure
Description: Children will have to wear a 'seasickness-band', which has the effect of acupressure
Study NCT02660970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-band
Description: Children will have to wear a 'placebo-wristband'
Study NCT02660970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iberogast
Description: Children will have to take Iberogast drops
Study NCT02660970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-drops
Description: Children will have to take placebo-drops
Study NCT02954211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere.
Study NCT02954211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
Study NCT03698084 — intervention group
Intervention type: PROCEDURE
Intervention: venepuncture
Description: sample collection for analysis
Study NCT03698084 — intervention group
Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: sample collection for analysis
Study NCT00052364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00052364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01338675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study NCT02350244 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer program
Description: Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
Study NCT02350244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer program
Description: Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
Study NCT00806689 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac rhythm monitor implantation
Description: post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
Study NCT00806689 — intervention group
Intervention type: DEVICE
Intervention: Reveal® XT 9525
Description: During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
Study NCT00425334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 mL or 500 mL Hemospan (MP4OX)
Study NCT00425334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: 250 mL or 500 mL Ringer's lactate USP
Study NCT02138396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: A single dose of fentanyl, 400 mcg per sublingual spray
Study NCT04209205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457 6 mg/kg i.v.
Description: AIN457 6 mg/kg delivered by i.v. infusion
Study NCT02138396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection (FCI)
Description: A single dose of fentanyl citrate, 100 mcg per intramuscular injection
Study NCT04209205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457 i.v. infusion
Study NCT02138396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
Study NCT01017341 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: PSU hip protector
Description: hip protetor
Study NCT04350905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mosquito Feeding
Description: Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
Study NCT03700736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Moms
Description: The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
Study NCT01965418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fufang Biejia Ruangan Tablet
Study NCT01965418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00505102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: cyclosporine dose reduced of 50% after introduction of everolimus
Study NCT02565615 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Because this is a non-interventional study, there is no intervention here.
Study NCT00861679 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transplantation with Stem Cells from Umbilical Cord
Description: According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided.
Study NCT02741219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Control Group receives normal saline bolus after delivery
Study NCT02741219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
Study NCT02741219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: sufentanil PCA after surgery
Study NCT00956761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine (MF59C.1)
Description: 1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
Study NCT00989508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study NCT02741219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil and dexmedetomidine
Description: sufentanil combined with dexmedetomidine PCA after surgery
Study NCT00959530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lingualized occlusion
Description: occlusal surface arranged by lingualized occlusion
Study NCT00959530 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full Bilaterally Balanced Articulation
Description: occlusal surface arranged by Full Bilaterally Balanced Articulation
Study NCT02790463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-Led Intervention
Description: Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
Study NCT02873364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (High dose)
Description: Daily 4000 unites vitamin D
Study NCT02873364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Low dose)
Description: Daily 600 unites vitamin D
Study NCT01852929 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subject using usual positive airway pressure therapy while sleeping for one night
Description: Participants use their usual positive airway pressure therapy while sleeping overnight
Study NCT02832596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
Study NCT02832596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintained blood pressure
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Study NCT02155348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral cataract surgery with implantation of multifocal IOLs
Description: Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
Study NCT02155348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral cataract surgery with monovision
Description: Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
Study NCT02155348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lentis LS-313
Study NCT03865511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAGRISSO® 80mg (Osimertinib)
Description: Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.